Updating results

302 results for breast cancer Sort: Relevance | Date

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

Evidence-based recommendations on familial (inherited) breast cancer and related risks for people with a family history of breast cancer

Clinical guideline Published June 2013 Last updated March 2017

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated September 2017

Familial breast cancer

Everything NICE has said on assessing and managing familial breast cancer and related risks in people with a family history in an interactive flowchart

NICE Pathway Published October 2011 Last updated September 2017

Early and locally advanced breast cancer

Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated September 2017

Advanced breast cancer: diagnosis and treatment (CG81)

Evidence-based recommendations on diagnosing and treating advanced (stage 4) breast cancer (invasive adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated August 2017

Early and locally advanced breast cancer: diagnosis and treatment (CG80)

Evidence-based recommendations on diagnosing and treating early and locally advanced (stage 1 & 2) breast cancer (adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated March 2017

Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer (keyhole removal of breast tissue)

Interventional procedures guidance Published April 2009

Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment

Interventional procedures guidance Published January 2012

Interstitial laser therapy for breast cancer (IPG89)

Evidence-based recommendations on interstitial laser therapy for treating breast cancer

Interventional procedures guidance Published September 2004

Improving outcomes in breast cancer (CSG1)

Evidence-based recommendations on improving outcomes in breast cancer

Cancer service guideline Published August 2002

Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer

Interventional procedures guidance Published December 2005

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

Evidence summary Published March 2013

Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

Evidence-based recommendations on brachytherapy as the only type of adjuvant radiotherapy for breast cancer after local excision

Interventional procedures guidance Published July 2008

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Technology appraisal guidance In development

Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

Evidence-based recommendations on paclitaxel (Taxol) for adjuvant treatment of early node-positive breast cancer

Technology appraisal guidance Published September 2006

Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)

Evidence-based recommendations on docetaxel (Taxotere) for adjuvant treatment of early node-positive breast cancer

Technology appraisal guidance Published September 2006 Last updated March 2014

Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer

Technology appraisal guidance Published March 2002

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

Evidence-based recommendations on trastuzumab (Herceptin) for adjuvant treatment of early-stage HER2-positive breast cancer

Technology appraisal guidance Published August 2006 Last updated March 2014

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

Evidence-based recommendations on hormonal therapies (anastrozole/exemestane/letrozole) as extra treatment for early oestrogen-receptor-positive breast cancer

Technology appraisal guidance Published November 2006

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (early) - intrabeam radiotherapy system [ID618]

In development [GID-TAG353] Expected publication date: TBC

Technology appraisal guidance In development

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017

MIB76: Axxent electronic brachytherapy system for early stage breast cancer

Advice on the use of the Axxent electronic brachytherapy system for treating early stage breast cancer to aid local decision-making

Medtech innovation briefing Published August 2016

Fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951]

In development [GID-TA10106] Expected publication date: 20 December 2017

Technology appraisal guidance In development

MIB111: L-Dex U400 for lymphoedema after breast cancer treatment

Advice on the use of L-Dex U400 for lymphoedema (lymphedema) after breast cancer treatment to aid local decision-making

Medtech innovation briefing Published July 2017

ES15: Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (hormone-receptor positive, HER2-negative) - palbociclib [ID915]

In development [GID-TA10068] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964]

In development [GID-TA10030] Expected publication date: 21 December 2016

Technology appraisal guidance In development

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]

In development [GID-TAG322] Expected publication date: TBC

Technology appraisal guidance In development

MIB27: The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence

Advice on the use of the Prosigna gene expression profiling assay for assessing long-term risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published March 2015

Breast cancer

Everything NICE has produced on the topic of breast cancer.

MIB44: EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence

Advice on the use of the EndoPredict gene expression profiling assay for assessing the risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published November 2015

Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen [ID1072]

In development [GID-TA10094] Expected publication date: TBC

Technology appraisal guidance In development

Palbociclib for treating hormone-receptor positive, HER2-negative breast cancer [ID916]

In development [GID-TA10095] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer mortality rates

Breast cancer mortality rates Subject(s): Cancer NICE identity code: CCG04 Key Documents...

CCG indicator Published June 2016